Advertisement

World Journal of Surgery

, Volume 41, Issue 2, pp 423–432 | Cite as

Triple Antithrombotic Therapy and Outcomes in Post-PCI Patients Undergoing Non-cardiac Surgery

  • Javier A. Valle
  • Laura Graham
  • Aerin DeRussy
  • Kamal Itani
  • Mary T. Hawn
  • Thomas M. Maddox
Original Scientific Report
  • 308 Downloads

Abstract

Background

Triple therapy, or the use of anticoagulants with dual antiplatelet therapy (DAPT), is often used to protect against ischemic events in post-percutaneous coronary intervention (PCI) patients with indications for anticoagulation, but is associated with increased bleeding. As both ischemic and bleeding risks increase in the perioperative period, the impact of triple therapy may be especially pronounced in patients undergoing surgery. Outcomes in this population are currently unknown.

Methods

We identified patients undergoing non-cardiac surgeries within 2 years of PCI in Veterans Affairs hospitals from 2004 to 2012. We compared perioperative major adverse cardiovascular and cerebrovascular events (MACCE: mortality, myocardial infarction, stroke, revascularization) and bleeding events (in-hospital bleeding, transfusion) between surgeries in patients prescribed triple therapy and DAPT, adjusting for clinical, demographic, and operative characteristics.

Results

Among 7811 surgeries, 391 (5.0 %) occurred in patients receiving triple therapy. 44 (11.3 %) MACCE and 107 (27.4 %) bleeding events occurred with surgeries in triple therapy patients, compared to 366 (4.9 %) MACCE and 980 (13.2 %) bleeding events in DAPT patients. After adjustment, surgery in triple therapy patients was associated with higher rates of MACCE [odds ratio (OR) 1.65, 95 % confidence interval (CI) 1.16–2.34] or bleeding (OR 1.52, 95 % CI 1.17–1.99) as compared to surgery in DAPT patients.

Conclusions

One in twenty post-PCI patients undergoing non-cardiac surgery were on triple therapy. Surgery in these patients was associated with higher MACCE and bleeding events compared to surgery in patients on DAPT, independent of clinical and operative characteristics. These findings identify a high-risk population for surgery, which may warrant increased surveillance for adverse perioperative events.

Keywords

Clopidogrel Triple Therapy Bleeding Event Prasugrel Ticagrelor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

There are no relationships with industry to disclose. Dr. Valle is supported by a NIH T32 training Grant HL0782 at the University of Colorado, Aurora, CO.

Supplementary material

268_2016_3725_MOESM1_ESM.docx (89 kb)
Supplementary material 1 (DOCX 89 kb)

References

  1. 1.
    Ruiz-Nodar JM, Marin F, Hurtado JA et al (2008) Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol 51:818–825CrossRefPubMedGoogle Scholar
  2. 2.
    Hansen ML, Sorensen R, Clausen MT et al (2010) Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 170:1433–1441CrossRefPubMedGoogle Scholar
  3. 3.
    Lamberts M, Gislason GH, Lip GY et al (2014) Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. Circulation 129:1577–1585CrossRefPubMedGoogle Scholar
  4. 4.
    Lamberts M, Gislason GH, Olesen JB et al (2013) Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol 62:981–989CrossRefPubMedGoogle Scholar
  5. 5.
    Lamberts M, Olesen JB, Ruwald MH et al (2012) Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation 126:1185–1193CrossRefPubMedGoogle Scholar
  6. 6.
    Nikolsky E, Mehran R, Dangas GD et al (2012) Outcomes of patients treated with triple antithrombotic therapy after primary percutaneous coronary intervention for ST-elevation myocardial infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI] trial). Am J Cardiol 109:831–838CrossRefPubMedGoogle Scholar
  7. 7.
    Karjalainen PP, Porela P, Ylitalo A et al (2007) Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J 28:726–732CrossRefPubMedGoogle Scholar
  8. 8.
    Dewilde WJ, Oirbans T, Verheugt FW et al (2013) Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 381:1107–1115CrossRefPubMedGoogle Scholar
  9. 9.
    Dans AL, Connolly SJ, Wallentin L et al (2013) Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation 127:634–640CrossRefPubMedGoogle Scholar
  10. 10.
    Lip GY, Huber K, Andreotti F et al (2010) Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Thromb Haemost 103:13–28CrossRefPubMedGoogle Scholar
  11. 11.
    January CT, Wann LS, Alpert JS et al (2014) AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 130:2071–2104CrossRefPubMedGoogle Scholar
  12. 12.
    Lip GY, Windecker S, Huber K et al (2014) Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 35:3155–3179CrossRefPubMedGoogle Scholar
  13. 13.
    Mangano DT, Browner WS, Hollenberg M, Li J, Tateo IM (1992) Long-term cardiac prognosis following noncardiac surgery. The Study of Perioperative Ischemia Research Group. JAMA J Am Med Assoc 268:233–239CrossRefGoogle Scholar
  14. 14.
    Mangano DT, Browner WS, Hollenberg M, London MJ, Tubau JF, Tateo IM (1990) Association of perioperative myocardial ischemia with cardiac morbidity and mortality in men undergoing noncardiac surgery. The Study of Perioperative Ischemia Research Group. N E J Med 323:1781–1788CrossRefGoogle Scholar
  15. 15.
    Kitchen L, Erichson RB, Sideropoulos H (1982) Effect of drug-induced platelet dysfunction on surgical bleeding. Am J Surg 143:215–217CrossRefPubMedGoogle Scholar
  16. 16.
    Patterson BM, Marchand R, Ranawat C (1989) Complications of heparin therapy after total joint arthroplasty. J Bone Joint Surg Am 71:1130–1134CrossRefPubMedGoogle Scholar
  17. 17.
    Lazio BE, Simard JM. Anticoagulation in neurosurgical patients. Neurosurgery 1999;45:838-47; discussion 847-8Google Scholar
  18. 18.
    McKenna R (2001) Abnormal coagulation in the postoperative period contributing to excessive bleeding. Med Clin N Am 85:1277–1310, viiiCrossRefPubMedGoogle Scholar
  19. 19.
    Hawn MT, Graham LA, Richman JS, Itani KM, Henderson WG, Maddox TM (2013) Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents. JAMA J Am Med Assoc 310:1462–1472CrossRefGoogle Scholar
  20. 20.
    Maddox TM, Plomondon ME, Petrich M et al (2014) A national clinical quality program for Veterans Affairs catheterization laboratories (from the Veterans Affairs clinical assessment, reporting, and tracking program). Am J Cardiol 114:1750–1757CrossRefPubMedGoogle Scholar
  21. 21.
    Hynes DM, Perrin RA, Rappaport S, Stevens JM, Demakis JG (2004) Informatics resources to support health care quality improvement in the veterans health administration. J Am Med Inform Assoc JAMIA 11:344–350CrossRefPubMedGoogle Scholar
  22. 22.
    Perrin R, Bates J, Noel PH, Copeland LA, Lancaster B (2008) National clinical data for VA research: the VA corporate data warehouse. In: HSR&D national meeting, Baltimore, MD. Department of Veterans Affairs, Washington, DCGoogle Scholar
  23. 23.
    Lee TH, Marcantonio ER, Mangione CM et al (1999) Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation 100:1043–1049CrossRefPubMedGoogle Scholar
  24. 24.
    Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137:263–272CrossRefPubMedGoogle Scholar
  25. 25.
    Douketis JD, Spyropoulos AC, Kaatz S et al (2015) Perioperative bridging anticoagulation in patients with atrial fibrillation. N E J Med 373:823–833CrossRefGoogle Scholar
  26. 26.
    Fosbol EL, Wang TY, Li S et al (2013) Warfarin use among older atrial fibrillation patients with non-ST-segment elevation myocardial infarction managed with coronary stenting and dual antiplatelet therapy. Am Heart J 166:864–870CrossRefPubMedGoogle Scholar
  27. 27.
    Ko DT, Yun L, Wijeysundera HC et al (2010) Incidence, predictors, and prognostic implications of hospitalization for late bleeding after percutaneous coronary intervention for patients older than 65 years. Circ Cardiovasc Interv 3:140–147CrossRefPubMedGoogle Scholar
  28. 28.
    Shroff GR, Solid CA, Herzog CA (2013) Temporal trends in ischemic stroke and anticoagulation therapy among Medicare patients with atrial fibrillation: a 15-year perspective (1992–2007). JAMA Intern Med 173:159–160CrossRefPubMedGoogle Scholar
  29. 29.
    Maier B, Hegenbarth C, Theres H, Schoeller R, Schuehlen H, Behrens S (2014) Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome in the real world: data from the Berlin AFibACS Registry. Cardiol J 21:465–473CrossRefPubMedGoogle Scholar
  30. 30.
    Razouki Z, Ozonoff A, Zhao S, Jasuja GK, Rose AJ (2014) Improving quality measurement for anticoagulation: adding international normalized ratio variability to percent time in therapeutic range. Circ Cardiovasc Qual Outcomes 7:664–669CrossRefPubMedGoogle Scholar
  31. 31.
    Roy P, Bonello L, Torguson R et al (2009) Temporal relation between Clopidogrel cessation and stent thrombosis after drug-eluting stent implantation. Am J Cardiol 103:801–805CrossRefPubMedGoogle Scholar
  32. 32.
    Naidu SS, Krucoff MW, Rutledge DR et al (2012) Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8061-patient XIENCE V United States study. JACC Cardiovascular interventions 5:626–635CrossRefPubMedGoogle Scholar
  33. 33.
    Gibson CM, Mehran R, Bode C et al (2015) An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Am Heart J 169:472–478.e5CrossRefPubMedGoogle Scholar
  34. 34.
    Clinicaltrials.gov. Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)Google Scholar
  35. 35.
    Amlani S, Nadarajah T, Afzal R, Pal-Sayal R, Eikelboom JW, Natarajan MK (2010) Mortality and morbidity following a major bleed in a registry population with acute ST elevation myocardial infarction. J Thromb Thrombolysis 30:434–440CrossRefPubMedGoogle Scholar
  36. 36.
    Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KAA, Yusuf S (2006) Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114:774–782CrossRefPubMedGoogle Scholar
  37. 37.
    Sarafoff N, Martischnig A, Wealer J et al (2013) Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. J Am Coll Cardiol 61:2060–2066CrossRefPubMedGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2016

Authors and Affiliations

  • Javier A. Valle
    • 1
    • 5
  • Laura Graham
    • 2
  • Aerin DeRussy
    • 2
  • Kamal Itani
    • 3
  • Mary T. Hawn
    • 4
  • Thomas M. Maddox
    • 1
  1. 1.VA Eastern Colorado Health Care SystemUniversity of Colorado School of MedicineDenverUSA
  2. 2.Birmingham Veterans Affairs Medical CenterBirminghamUSA
  3. 3.Veterans Affairs Boston Health Care SystemBoston University and Harvard Medical SchoolBostonUSA
  4. 4.Stanford University School of MedicinePalo AltoUSA
  5. 5.Division of CardiologyUniversity of Colorado HospitalAuroraUSA

Personalised recommendations